D. E. Shaw & Co. Inc. Trims Stake in Health Catalyst, Inc. (NASDAQ:HCAT)

D. E. Shaw & Co. Inc. cut its stake in Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) by 86.0% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 12,965 shares of the company's stock after selling 79,341 shares during the quarter. D. E. Shaw & Co. Inc.'s holdings in Health Catalyst were worth $92,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the stock. Deutsche Bank AG grew its position in shares of Health Catalyst by 9.5% in the fourth quarter. Deutsche Bank AG now owns 225,768 shares of the company's stock valued at $1,596,000 after purchasing an additional 19,659 shares in the last quarter. Daventry Group LP grew its position in Health Catalyst by 3.8% during the fourth quarter. Daventry Group LP now owns 2,509,480 shares of the company's stock worth $17,742,000 after buying an additional 91,878 shares in the last quarter. Cubist Systematic Strategies LLC grew its position in Health Catalyst by 34.9% during the fourth quarter. Cubist Systematic Strategies LLC now owns 137,670 shares of the company's stock worth $973,000 after buying an additional 35,584 shares in the last quarter. Caption Management LLC grew its position in Health Catalyst by 157.9% during the fourth quarter. Caption Management LLC now owns 45,137 shares of the company's stock worth $319,000 after buying an additional 27,637 shares in the last quarter. Finally, Brevan Howard Capital Management LP purchased a new position in Health Catalyst during the fourth quarter worth about $92,000. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, COO Daniel Lesueur sold 16,902 shares of the business's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $4.52, for a total value of $76,397.04. Following the completion of the sale, the chief operating officer now owns 216,250 shares of the company's stock, valued at approximately $977,450. The trade was a 7.25% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel Benjamin Landry sold 13,827 shares of the business's stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $4.55, for a total value of $62,912.85. Following the completion of the sale, the general counsel now directly owns 160,437 shares of the company's stock, valued at approximately $729,988.35. This trade represents a 7.93% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 41,147 shares of company stock valued at $182,284. Insiders own 2.50% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on HCAT. KeyCorp reduced their target price on Health Catalyst from $7.00 to $5.00 and set an "overweight" rating for the company in a research report on Wednesday, April 16th. Canaccord Genuity Group reduced their target price on Health Catalyst from $10.00 to $9.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Stifel Nicolaus boosted their target price on Health Catalyst from $5.00 to $5.50 and gave the stock a "hold" rating in a research report on Thursday, May 8th. Evercore ISI cut Health Catalyst from an "outperform" rating to an "inline" rating in a research report on Wednesday, April 9th. Finally, Royal Bank of Canada reduced their target price on Health Catalyst from $7.00 to $6.00 and set a "sector perform" rating for the company in a research report on Thursday, February 27th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $8.00.

Health Catalyst Price Performance

HCAT stock traded down $0.01 during mid-day trading on Monday, hitting $3.79. 948,319 shares of the stock were exchanged, compared to its average volume of 596,898. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. The business has a fifty day moving average price of $3.99 and a 200 day moving average price of $5.44. Health Catalyst, Inc. has a 12 month low of $3.49 and a 12 month high of $9.24. The stock has a market capitalization of $263.79 million, a price-to-earnings ratio of -2.81 and a beta of 1.56.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.